Effects of Naloxegol on Gastrointestinal Transit and Colonic Fecal Volume in Healthy Participants Receiving Oxycodone.
Analgesics
Constipation
Motility
Naloxegol
Oxycodone
opioid
Journal
Journal of neurogastroenterology and motility
ISSN: 2093-0879
Titre abrégé: J Neurogastroenterol Motil
Pays: Korea (South)
ID NLM: 101530189
Informations de publication
Date de publication:
30 Oct 2019
30 Oct 2019
Historique:
received:
09
05
2018
revised:
22
03
2019
accepted:
07
08
2019
entrez:
8
10
2019
pubmed:
8
10
2019
medline:
8
10
2019
Statut:
ppublish
Résumé
Opioids cause gastrointestinal (GI) dysmotility, decrease gut secretion, and affect gut sphincters. Symptoms of opioid-induced bowel dysfunction may be alleviated by peripherally acting opioid antagonists like naloxegol, but detailed knowledge on GI effects of this drug is lacking. We hypothesized that naloxegol, compared to placebo, would reduce GI transit time and colonic fecal volume in opioid-treated healthy participants. We conducted a randomized, double-blinded, single-center, 2-way cross-over study in 24 healthy males, randomized to a 6 day treatment period of oxycodone (15 mg twice a day) co-administered with either naloxegol (25 mg once a day) or matching placebo. Participants swallowed an electromagnetic capsule which determined GI transit times. Colonic fecal volume was quantified with magnetic resonance imaging both pre-treatment and post-treatment. Naloxegol reduced total GI transit time by 21% (56 hours vs 71 hours, Short-term administration of naloxegol in healthy participants reverses the retardation of total GI and colonic transit induced by oxycodone. This supports the use of naloxegol in the treatment of GI side effects to opioid treatment, and add knowledge to the current understanding of mechanisms behind peripherally-acting opioid antagonists.
Sections du résumé
BACKGROUND/AIMS
OBJECTIVE
Opioids cause gastrointestinal (GI) dysmotility, decrease gut secretion, and affect gut sphincters. Symptoms of opioid-induced bowel dysfunction may be alleviated by peripherally acting opioid antagonists like naloxegol, but detailed knowledge on GI effects of this drug is lacking. We hypothesized that naloxegol, compared to placebo, would reduce GI transit time and colonic fecal volume in opioid-treated healthy participants.
METHODS
METHODS
We conducted a randomized, double-blinded, single-center, 2-way cross-over study in 24 healthy males, randomized to a 6 day treatment period of oxycodone (15 mg twice a day) co-administered with either naloxegol (25 mg once a day) or matching placebo. Participants swallowed an electromagnetic capsule which determined GI transit times. Colonic fecal volume was quantified with magnetic resonance imaging both pre-treatment and post-treatment.
RESULTS
RESULTS
Naloxegol reduced total GI transit time by 21% (56 hours vs 71 hours,
CONCLUSION
CONCLUSIONS
Short-term administration of naloxegol in healthy participants reverses the retardation of total GI and colonic transit induced by oxycodone. This supports the use of naloxegol in the treatment of GI side effects to opioid treatment, and add knowledge to the current understanding of mechanisms behind peripherally-acting opioid antagonists.
Identifiants
pubmed: 31587551
pii: jnm18079
doi: 10.5056/jnm18079
pmc: PMC6786453
doi:
Types de publication
Journal Article
Langues
eng
Pagination
602-610Références
Scand J Gastroenterol. 2011 Jul;46(7-8):895-902
pubmed: 21623673
Curr Pharm Des. 2012;18(37):6010-20
pubmed: 22747544
Scand J Pain. 2016 Apr;11:111-122
pubmed: 28850449
Int J Clin Pharmacol Ther. 2015 Oct;53(10):838-46
pubmed: 26329350
J Pain Symptom Manage. 2010 Nov;40(5):696-703
pubmed: 20727708
Clin Pharmacol Drug Dev. 2015 Nov;4(6):434-41
pubmed: 27137715
Aliment Pharmacol Ther. 2014 Oct;40(7):771-9
pubmed: 25112584
Am J Gastroenterol. 2010 Feb;105(2):403-11
pubmed: 19888202
J Neurogastroenterol Motil. 2016 Apr 30;22(2):282-91
pubmed: 26811503
Aliment Pharmacol Ther. 2007 Mar 1;25(5):599-608
pubmed: 17305761
Neurogastroenterol Motil. 2017 Jul;29(7):null
pubmed: 28086261
Aliment Pharmacol Ther. 2010 Oct;32(7):884-93
pubmed: 20839388
Neurogastroenterol Motil. 2004 Oct;16 Suppl 2:17-28
pubmed: 15357848
Neurogastroenterol Motil. 2015 Dec;27(12):1755-63
pubmed: 26598050
Pain. 2013 Sep;154(9):1542-50
pubmed: 23726675
Eur J Pharm Sci. 2018 May 30;117:187-192
pubmed: 29432808
Neurogastroenterol Motil. 2016 Jun;28(6):849-54
pubmed: 26871593
Scand J Pain. 2016 Apr;11:104-110
pubmed: 28850447
N Engl J Med. 2014 Jun 19;370(25):2387-96
pubmed: 24896818
J Neurogastroenterol Motil. 2015 Jul 30;21(3):423-32
pubmed: 26130638
J Pharmacol Exp Ther. 2017 May;361(2):280-291
pubmed: 28336575
Curr Opin Gastroenterol. 2008 Mar;24(2):149-58
pubmed: 18301264
Drugs. 2012 Oct 1;72(14):1847-65
pubmed: 22950533
Clin Gastroenterol Hepatol. 2005 Aug;3(8):784-91
pubmed: 16234007
Neurogastroenterol Motil. 2015 Mar;27(3):379-88
pubmed: 25557630
Eur J Gastroenterol Hepatol. 2016 May;28(5):514-24
pubmed: 26795566
J Clin Gastroenterol. 1992 Dec;15(4):321-4
pubmed: 1294638
Aliment Pharmacol Ther. 2008 Jun;27(12):1224-32
pubmed: 18363893
Neurogastroenterol Motil. 2010 Apr;22(4):424-30, e96
pubmed: 20100280
J Clin Pharmacol. 2014 Dec;54(12):1375-82
pubmed: 24946021
Neurogastroenterol Motil. 2014 Dec;26(12):1783-91
pubmed: 25348504
Abdom Imaging. 2015 Oct;40(7):2232-41
pubmed: 26054979